Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideVRTXVertex Pharmaceuticals
FinDog View：Neutral
| Metric | AMGN | VRTX |
|---|
| Close | 376.35 | 513.26 |
| Market Cap | $203B | $121B |
| 1M | −10.26% | −0.44% |
| P/E (TTM) | 23.3 | 29.7 |
| Forward P/E | 16.9 | 24.0 |
| P/E 5-Yr Percentile | 27 | 52 |
| P/S | 5.4 | 10.4 |
| P/B | 17.4 | 6.5 |
| Dividend Yield | 3.21% | — |
| Latest Quarter Revenue | $10.1B | $3.3B |
| Revenue YoY | +9.5% | +12.5% |
| Gross Margin | 72.0% | 85.3% |
| Latest Quarter EPS | 4.37 | 4.31 |
| Avg Post-Earnings Move | ±5.2% | ±6.7% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.60% | 1.66% |
| 90-Day Net Insider Buying | −$4.1M | −$2.8M |
AMGN · Revenue, Last 8 Quarters ($B)
VRTX · Revenue, Last 8 Quarters ($B)
